Furthermore, recent studies using the GIPR antagonist GIP(3-30)NH2 in patients with T2D established that endogenous GIP makes a substantial contribution to β-cell function and blood glucose control in the presence of DPP4 inhibitors [262]. This evidence concerns the gene GIPR and type 2 diabetes mellitus.